Table 2.
Baseline patient characteristics
| Baseline patient characteristics | N = 1758 patients |
|---|---|
| Demographics | |
| Age (years), mean (min–max) | 61.6 (19–92) |
| Female, % | 34.2% |
| BMI (kg/m2), mean (min–max) | 26.7 (15–52) |
| CHA2DS2-Vasc score, mean (min–max) | 2.1 (0–9) |
| Echocardiography parameters | |
| Left atrial diameter (mm), mean (min–max) | 39 (16–73) |
| LVEF (%), mean (min–max) | 54.7% (14–80) |
| Patients with LVEF < 40%, % | 4.7% |
| Past medical history | |
| Hypertension (%) | 59.1% |
| Diabetes mellitus (%) | 12.7% |
| Congestive heart failure (%) | 12.3% |
| Coronary artery disease (%) | 12.7% |
| Stroke/TIA | 6.2% |
| Medications | |
| Failed Class I or III antiarrhythmic drug (%) | 38.2% |
| Failed Class I, II, III or IV antiarrhythmic drug (%) | 65.4% |
| Vitamin K antagonist (%) | 5.1% |
| NOAC (%) | 88.3% |
| No prior oral anticoagulation (%) | 7.7% |
| Indication for ablation | |
| Paroxysmal atrial fibrillation (%) | 57.5% |
| Persistent atrial fibrillation (%) | 35.2% |
| Long standing persistent atrial fibrillation (%) | 3.9% |
| Atrial flutter (%) | 1.1% |
| Other (%) | 2.9% |
| First-ever ablation procedure (%) | 93.5% |
LVEF, left ventricular ejection fraction; NOAC, non-vitamin K antagonist oral anticoagulants.